14.22
-0.11 (-0.77%)
| Previous Close | 14.33 |
| Open | 14.19 |
| Volume | 1,437,092 |
| Avg. Volume (3M) | 1,745,450 |
| Market Cap | 1,396,597,376 |
| Price / Sales | 9.21 |
| Price / Book | 5.15 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Profit Margin | -16.11% |
| Operating Margin (TTM) | -466.29% |
| Diluted EPS (TTM) | -0.160 |
| Quarterly Revenue Growth (YOY) | 4,900.00% |
| Total Debt/Equity (MRQ) | 30.33% |
| Current Ratio (MRQ) | 11.00 |
| Operating Cash Flow (TTM) | -20.48 M |
| Levered Free Cash Flow (TTM) | -9.60 M |
| Return on Assets (TTM) | -6.10% |
| Return on Equity (TTM) | -6.91% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | ARS Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Average | 1.13 |
|
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 16.93% |
| % Held by Institutions | 80.28% |
| 52 Weeks Range | ||
| Median | 40.00 (181.29%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Roth Capital | 04 Sep 2025 | 40.00 (181.29%) | Buy | 10.69 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 17 Sep 2025 | Announcement | ADARx Pharmaceuticals Appoints Industry Veteran, Laura Shawver, Ph.D., as Board Chair |
| 08 Sep 2025 | Announcement | Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis |
| 28 Aug 2025 | Announcement | ARS Pharmaceuticals to Participate in Upcoming Investor Conferences |
| 13 Aug 2025 | Announcement | ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray) |
| 04 Aug 2025 | Announcement | ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results |
| 18 Jul 2025 | Announcement | EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |